10-K · March 5, 2026
Lexicon’s 2025 results show a sharp rebound in reported revenue driven by collaboration/licensing proceeds (Novo Nordisk $45.0M upfront) and a materially narrower net loss (‑$50.3M vs ‑$200.4M in 2024) after large…
Earnings analysis · 10-Q
LXRX earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Lexicon Pharmaceuticals reported disappointing Q1 2026 results with revenues of only $1.09 million, missing estimates of $9.57 million by a significant margin. EPS was flat at $0.00, slightly exceeding expectations of…
Read full summary
Lexicon Pharmaceuticals reported disappointing Q1 2026 results with revenues of only $1.09 million, missing estimates of $9.57 million by a significant margin. EPS was flat at $0.00, slightly exceeding expectations of -$0.04. The company noted challenges in maintaining its financial position and addressing a high cash burn rate.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.0
What stood out
-
Revenue Falls Short of Expectations
Actual revenue of $1.09M significantly missed the estimated $9.57M by 88.6%.
-
EPS Matches Expectations
Reported EPS was $0.00, slightly better than the expected -$0.04.
-
Cash Burn Rate Remains High
Continues to experience negatives with high cash burn, affecting liquidity.
What to watch
-
High Cash Burn Rate
Company reported ongoing high cash burn, affecting liquidity and future operations.
-
Dependence on Drug Development Success
Risk of failure in R&D could adversely affect future revenue and stock price.
-
Regulatory Approval Uncertainties
Lengthy regulatory processes may lead to delays in product commercialization.
Management's outlook
Outlook deferred to earnings press release / call.
Earlier filings 4
10-Q · May 14, 2025
Lexicon reported Q1 2025 revenue of $1,262,000 (net product revenue) and a net loss of $25,295,000 (EPS $(0.07)), an improvement versus Q1 2024 net loss of $48,397,000 (EPS $(0.20)). The quarter reflects a one-time…
10-K · March 7, 2025
Lexicon pivoted in 2024 toward commercialization and licensing while continuing R&D on pilavapadin (LX9211), LX9851 and sotagliflozin. Revenue rose to approximately $31.1 million in 2024 driven by a $25.0 million…
10-Q · November 13, 2024
Lexicon reported Q3 net revenue of $1,750,000 and maintained a high gross margin (~95.9%), but posted a large operating loss of $63,693,000 and a net loss of $64,811,000 (EPS -$0.18). Liquidity was materially…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.